Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Proven Endpoints LLC

Neither a doctor nor a teaching hospital

Research payments

$1,046,655

429 payments

Through program year 2025, Proven Endpoints LLC is reported as receiving $1,046,655 in research payments, across 429 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $429,584 156
2024 Research $429,983 192
2023 Research $187,087 81

Breakdown

Who paid Research payments · program years 2023–2025
  1. AbbVie, Inc. $899,069 344 payments
  2. Eli Lilly and Company $69,767 2 payments
  3. Teva Pharmaceuticals USA, Inc. $58,233 78 payments
  4. H. Lundbeck A S $19,585 5 payments
Studies the money was for Research payments · program years 2023–2025
  1. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $340,570 108 payments
  2. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine $130,544 60 payments
  3. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $102,647 47 payments
  4. A Randomized, Double Blind, Placebo Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine the Rebuild 2 Study $69,767 2 payments
  5. Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine $57,595 35 payments
  6. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years $50,784 12 payments
  7. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $42,909 8 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $38,371 39 payments
  9. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $33,859 16 payments
  10. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $33,342 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record